表紙:Ilaris-医薬品の洞察と市場予測:2030年
市場調査レポート
商品コード
974758

Ilaris-医薬品の洞察と市場予測:2030年

Ilaris- Drug Insight and Market Forecast - 2030

出版日: 受注後作成 | 発行: DelveInsight Business Research LLP | ページ情報: 英文 60 Pages | 納期: 2~10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=134.18円
Ilaris-医薬品の洞察と市場予測:2030年
出版日: 受注後作成
発行: DelveInsight Business Research LLP
ページ情報: 英文 60 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Canakinumabは、Ilarisのブランド名で販売されており、全身性若年性特発性関節炎および成人発症スティル病を含む活動性スティル病の治療薬です。インターロイキン-1ベータを標的としたヒトモノクローナル抗体です。

2020年6月、Novartis ILARIS(Canakinumab)は、成人発症スティル病(AOSD)1を治療するための新しい適応症について米国食品医薬品局(FDA)の承認を受けました。 FDAは、全身性若年性特発性関節炎(SJIA)と2歳以上の患者のAOSDの両方を含む活動性スティル病の適応症を認めました。

世界中での広範な研究と増加するヘルスケア費のため、今後数年間で、Ilarisの市場シナリオは変化するとみられています。これにより、市場の規模が拡大し、製薬会社がより多くの市場に参入できるようになります。

企業や学術関係者は、課題の評価とともに、Ilarisの優位性に影響を与える可能性のある機会を模索しています。開発中の治療法は、病状を治療/改善するための新しいアプローチに焦点を合わせています。

Ilarisのためのその他の新製品はIlarisと市場で競合しており、近い将来、新興の治療法が上市されることで市場に大きな影響を与えるでしょう。

規制のマイルストーン、開発活動、およびいくつかの重要な研究結果は、Ilarisの現在の開発シナリオを提供します。

2020年から2030年までのIlarisの予測売上データを詳細に分析することで、Ilarisの全体的なシナリオを特定し、治療ポートフォリオに関する意思決定プロセスにおいてクライアントをサポートします。

当レポートは、7つの主要市場におけるIlarisの治験薬について包括的に扱います。2020年から2030年までの調査期間における、米国、欧州5ヶ国(ドイツ、フランス、イタリア、スペイン、英国)、および日本の7つの主要市場におけるIlarisの詳細な概要を製品の詳細とともに提供します。製品の詳細には、作用機序、投与量と管理、合成経路、規制のマイルストーンを含む研究開発活動、およびその他の開発活動が含まれます。さらに、市場予測、 SWOT分析、市場における競合動向、およびその他の新たな治療法など将来の市場動向を提供しています。

目次

第1章 製品の概要

  • 表示
  • 作用機序
  • 投薬と管理
    • 剤形と濃度
  • 合成経路
  • 薬理学
    • 薬力学
    • 薬物動態
  • 副作用
  • 製品のスナップショット
  • Ilarisの開発マイルストーン
  • 市販の詳細
    • 米国
    • 欧州
    • 日本
  • 特許の詳細

第2章 SWOT分析

  • アナリストの見解

第3章 規制のマイルストーン

  • 承認
  • 研究開発
  • 臨床試験情報
  • 安全性と有効性
  • 製品開発活動

第4章 市場評価

  • 主要7ヶ国市場分析
  • 米国
  • 欧州
  • 日本
  • 主な調査結果

第5章 市場の競合動向

第6章 新たな治療法

第7章 付録

  • レポート購入オプション
図表

List of Tables

  • Table 1 Ilaris, Description
  • Table 2 Ilaris, Trial Diversification
  • Table 3 Ilaris, Marketed Details United States
  • Table 4 Ilaris, Marketed Details Europe
  • Table 5 Ilaris, Marketed Details Japan
  • Table 6 Patent Details: Ilaris
  • Table 7 Ilaris, Clinical Trial Description, 2020
  • Table 8 Safety and Efficacy Results for Ilaris
  • Table 9 Ilaris, 7MM Market Size from 2017 to 2030 (in Million USD)
  • Table 10 Ilaris, US Market Size from 2017 to 2030 (in Million USD)
  • Table 11 Ilaris, EU Market Size from 2017 to 2030 (in Million USD)
  • Table 12 Ilaris, EU5 Market Size from 2017 to 2030 (in Millions USD)
  • Table 13 Ilaris, Japan Market Size from 2017 to 2030 (in Million USD)
  • Table 14 Market Competitors
  • Table 15 Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of Ilaris
  • Figure 2 Patent Details, Ilaris
  • Figure 3 Ilaris, 7MM Market Size from 2017 to 2030 (in Million USD)
  • Figure 4 Ilaris, US Market Size from 2017 to 2030 (in Millions USD)
  • Figure 5 Ilaris, EU Market Size from 2017 to 2030 (in Millions USD)
  • Figure 6 Ilaris, EU5 Market Size from 2017 to 2030 (in Millions USD)
  • Figure 7 Ilaris, Japan Market Size from 2017 to 2030 (in Millions USD)
目次
Product Code: DIDM0139

"Ilaris- Drug Insight and Market Forecast - 2030" report by DelveInsight outlays comprehensive insights of the product indicated for the treatment of its approved condition. A detailed picture of the Ilaris in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2017-2030 is provided in this report along with a detailed description of the product. The product details covers mechanism of action, dosage and administration, route of synthesis, and pharmacological studies, including product marketed details, regulatory milestones, and other development activities. Further, it also consists of market assessments inclusive of the market forecast, SWOT analysis, and detailed analyst views. It further highlights the market competitors, late-stage emerging therapies, and patent details in the global space.

Drug Summary:

Canakinumab, sold under the brand name Ilaris is a medication for the treatment of systemic juvenile idiopathic arthritis and active Still's disease, including adult-onset Still's disease. It is a human monoclonal antibody targeted at interleukin-1 beta.

In June 2020, Novartis ILARIS (canakinumab) received US Food and Drug Administration (FDA) approval for a new indication to treat Adult-Onset Still's Disease (AOSD)1. The FDA granted an indication for active Still's disease including both systemic juvenile idiopathic arthritis (SJIA) and AOSD in patients aged 2 years and older.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, route of synthesis, pharmacological studies (pharmacodynamics and pharmacokinetics) and adverse reactions.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug marketed details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around Ilaris.
  • The report contains historical and forecasted sales for Ilaris till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) in the space with a brief snapshot of the details.
  • The report also features the SWOT analysis with analyst insights and key findings of Ilaris.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Ilaris Analytical Perspective by DelveInsight

  • In-depth Ilaris Market Assessment

This report provides a detailed market assessment of Ilaris in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides historical and forecasted sales data from 2017 to 2030.

  • Ilaris Clinical Assessment

The report provides the clinical trials information of Ilaris covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Ilaris is set to change due to the extensive research in the treatment of the indicated condition and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Ilaris dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other approved products for the disease are giving market competition to Ilaris and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current market scenario of Ilaris.
  • Our in-depth analysis of the sales data of Ilaris from 2017 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Ilaris in the market.

Key Questions:

  • What is the prescribed dosage and strengths of Ilaris are available in the market?
  • What are the common adverse reactions or side effects of Ilaris?
  • What is the product type, route of administration and mechanism of action of Ilaris?
  • What are the chemical specifications of Ilaris?
  • How are the clinical trials diversified on the basis of the trial status?
  • What is the history of Ilaris, and what is its future?
  • What are the marketed details of Ilaris in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • How many patents have been granted to Ilaris and when these patents will get expire?
  • What are the pros (benefits) and cons (disadvantages) of Ilaris?
  • In which countries Ilaris got approval and when it gets launched?
  • What are the clinical trials are currently ongoing for Ilaris?
  • How the safety and efficacy results determined the approval of Ilaris?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Ilaris development?
  • What are the key designations that have been granted to Ilaris?
  • What is the historical and forecasted market scenario of Ilaris?
  • How is the market trend of Ilaris is different in the Seven Major Markets (the United States, EU5 [Germany, France, Italy, Spain, and the United Kingdom], and Japan)?
  • What are the other approved products available and how these are giving competition to Ilaris?
  • Which are the late-stage emerging therapies under development for the treatment of the indicated condition?

Table of Contents

1. Product Overview

  • 1.1. Indication
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
    • 1.4.1 Dosage Forms and Strengths
  • 1.4. Route of Synthesis
  • 1.5. Pharmacology
    • 1.4.2 Pharmacodynamics
    • 1.4.3 Pharmacokinetics
  • 1.6. Adverse Reactions
  • 1.7. Product Snapshot
  • 1.8. Development Milestones of Ilaris
  • 1.9. Marketed Details
    • 1.4.4 United States
    • 1.4.5 Europe
    • 1.4.6 Japan
  • 1.10. Patent Details

2. SWOT Analysis

  • 2.1. Analyst Views

3. Regulatory Milestones

  • 3.1. Approvals
  • 3.2. Research and Development
  • 3.3. Clinical Trials Information
  • 3.4. Safety and Efficacy
  • 3.5. Product Developmental Activities

4. Market Assessment

  • 4.1. 7MM Market Analysis
  • 4.2. United States
  • 4.3. Europe
  • 4.4. Japan
  • 4.5. Key Findings

5. Market Competitors

6. Emerging Therapies

7. Appendix

  • 7.1. Report Purchase Options